Published in Women's Health Weekly, November 25th, 2004
HER2-positive breast cancer patients suffer from a particularly aggressive form of breast cancer with a poor prognosis. Herceptin is the only targeted treatment for HER2-positive breast cancer with demonstrated improved survival, so early and accurate determination of HER2 status is imperative.
"The approved use of a wider range of diagnostic tests will provide more options and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly